These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37885795)

  • 1. Primary Series and Booster Coronavirus Disease 2019 Vaccine Effectiveness in a Cohort of Healthcare Workers in Albania During a BA.1 and BA.2 Variant Period, January-May 2022.
    Finci I; Rojas Castro MY; Hasibra I; Sulo J; Fico A; Daja R; Vasili A; Kota M; Preza I; Mühlemann B; Drosten C; Pebody R; Lafond KE; Kissling E; Katz MA; Bino S
    Open Forum Infect Dis; 2023 Oct; 10(10):ofad479. PubMed ID: 37885795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary series COVID-19 vaccine effectiveness among healthcare workers in Albania, February-December 2021.
    Rubin-Smith JE; Castro MYR; Preza I; Hasibra I; Sulo J; Fico A; Daja R; Vasili A; Kota M; Schmid A; Sridhar S; Guseinova A; Boshevska G; Bejtja G; Mühlemann B; Drosten C; Jorgensen P; Pebody R; Kissling E; Lafond KE; Katz MA; Bino S
    IJID Reg; 2023 Sep; 8():19-27. PubMed ID: 37317681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: A prospective cohort study among healthcare workers in Azerbaijan, May-November 2021.
    Katz MA; Rojas Castro MY; Seyidov N; Herdman MT; Mehdiyev S; McKnight CJ; Guseinova A; Cojocaru R; Doran J; Mühlemann B; Drosten C; Suleymanova J; Pebody R; Kissling E; Hagverdiyev G
    Influenza Other Respir Viruses; 2023 Oct; 17(10):e13147. PubMed ID: 37799775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
    Cegolon L; Magnano G; Negro C; Larese Filon F;
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    Lind ML; Robertson AJ; Silva J; Warner F; Coppi AC; Price N; Duckwall C; Sosensky P; Di Giuseppe EC; Borg R; Fofana MO; Ranzani OT; Dean NE; Andrews JR; Croda J; Iwasaki A; Cummings DAT; Ko AI; Hitchings MDT; Schulz WL
    PLoS Med; 2022 Dec; 19(12):e1004136. PubMed ID: 36454733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States.
    Adams K; Rhoads JP; Surie D; Gaglani M; Ginde AA; McNeal T; Ghamande S; Huynh D; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hicks M; Hager DN; Ali H; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Lauring AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Chappell JD; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Lindsell CJ; Hart KW; Lester SN; Thornburg NJ; Park S; McMorrow ML; Patel MM; Tenforde MW; Self WH
    medRxiv; 2022 Jun; ():. PubMed ID: 35734090
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022.
    Cegolon L; Negro C; Mastrangelo G; Filon FL;
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692
    [No Abstract]   [Full Text] [Related]  

  • 13. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine effectiveness among healthcare workers: a hospital-based cohort study.
    Gaio V; Santos AJ; Amaral P; Faro Viana J; Antunes I; Pacheco V; Paiva A; Pinto Leite P; Antunes Gonçalves L; Araújo L; Silva A; Dias C; Kislaya I; Nunes B; Machado A
    BMJ Open; 2023 May; 13(5):e068996. PubMed ID: 37130692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020-2 April 2022.
    Cegolon L; Negro C; Pesce M; Filon FL
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851360
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.